ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

China approves 2 experimental corona vaccines for clinical trials

Nasdaq-listed Sinovac Biotech and Wuhan Institute of Biological Products join race

Two more pharmaceutical makers receive approvals to move potential coronavirus vaccines into clinical testing.   © Reuters

BEIJING (Reuters) -- China has approved early-stage human tests for two experimental vaccines to combat the new coronavirus that killed over 100,000 people worldwide, state media Xinhua reported on Tuesday.

The vaccines are being developed by a Beijing-based unit of Nasdaq-listed Sinovac Biotech, and by the Wuhan Institute of Biological Products, an affiliate of state-owned China National Pharmaceutical Group.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more